A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 593 participants.
Also called NCT03578809
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 593 participants
- Registry
-
NCT03578809
-
- Other papers using this trial's data
- Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Brazil, Czechia, Hungary, Israel, Netherlands, Poland, Russia, Slovakia, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03578809. Randomized; triple masking; primary purpose treatment. Start 2018-06-05 (actual); primary completion 2021-01-18 (actual). Results posted on 2022-02-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
- Acronym
- REAL-TIMI 63B
- Condition
- ST Elevation Myocardial Infarction
- Intervention (Biological)
- MEDI6012
- Intervention (Other)
- Placebo
- Lead sponsor
- MedImmune LLC
- Collaborator
- The TIMI Study Group
Record details
- Record id
cardio:ct-nct03578809- Content hash
857048fcfbe6db60a2d547f15ca5ee04e6d041aaedad8f2e5ff8d4332283ac03